Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Company release
Herantis Pharma Plc, Company release, 19 June 2024 at 9:15 p.m. EEST
Herantis Pharma: Disclosure of Major Holdings according to Chapter 9, Section 10 of the Finnish Securities Markets Act (19 April 2024)
Herantis Pharma Plc (“Herantis”), has on June 19, 2024, received a notification from Sp-Rahastoyhtiö Oy according to which the total number of Herantis shares owned by the investment funds of Sp-Rahastoyhtiö Oy (Säästöpankki Kotimaa and Säästöpankki Pienyhtiöt) is above five (5) per cent. The notification was made pursuant to chapter 9, section 5 of the Securities Market Act on 2 May 2024. Under the transition rules of the act 163/2024 amending the Finnish Securities Market Act (Amending Act), a shareholder in a First North listed company is required to notify major holdings within two months from the entry into force of the Amending Act. The notification has been made based on said transition rules, and not an acquisition or disposal of shares.
Herantis has one series of shares in which each share carries one vote. The percentages and numbers indicate the shareholding on the date the Amending Act entered into force on 19 April 2024.
| Total positions of Sp-Rahastoyhtiö Oy subject to the notification obligation: | ||||
| % of shares and voting rights (total of 7.A) | % of shares and voting rights through financial instruments (total of 7.B) | Total of both in % (7.A + 7.B) | Total number of shares and voting rights of issuer | |
| Resulting situation on the date on which threshold was crossed or reached | 5.48 | 5.48 | 20,160,733 | |
| Position of previous notification (if applicable) | ||||
| Notified details of the resulting situation on the date on which the threshold was crossed or reached: | ||||
| A: Shares and voting rights | ||||
Class/type of shares ISIN code (if possible) | Number of shares and voting rights | % of shares and voting rights | ||
Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | Direct (SMA 9:5) | Indirect (SMA 9:6 and 9:7) | |
| FI4000087861 | 1,105,620 | 5.4840 | ||
| SUBTOTAL A | 1,105,620 | 5.4840 | ||
| Information in relation to the person subject to the notification obligation | |||
| ☒ Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer. | |||
| ☐ Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity: | |||
| Name | % of shares and voting rights | % of shares and voting rights through financial instruments | Total of both |
For more information, please contact:
Tone Kvåle, CFO
Tel: +47 915 19576
Email: ir@herantis.com
Certified Advisor:
UB Corporate Finance Oy,
Finland: +358 9 25 380 225
ubcf@unitedbankers.fi
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com